BRAF突变在低级别胶质瘤中的预后作用:Meta分析
该Meta分析检索4个数据库,最终纳入8项研究共698例胶质瘤患者,评估BRAF V600E突变与低级别胶质瘤预后的关系。结果显示BRAF V600E与总生存改善相关(HR=0.64;95%CI=0.45-0.92),但无进展生存无统计学意义(HR=0.97;95%CI=0.7-1.36)。亚组分析提示该效应见于儿童患者而非成人。
要点
- BRAF V600E突变与低级别胶质瘤总生存改善相关(HR=0.64;95%CI=0.45-0.92)。
- 无进展生存未显示统计学显著差异(HR=0.97;95%CI=0.7-1.36)。
- 预后价值可能依赖年龄,儿童患者获益而成人无预后价值。
核心结论
- BRAF突变在低级别胶质瘤中具有有利的预后影响,其预后价值可能取决于患者年龄。
研究设计与样本
- Meta分析,检索PubMed、Web of Science、Embase和Cochrane四个电子数据库。
- 从483篇文章中最终纳入8篇文章,共698例胶质瘤患者。
- 采用逆方差加权随机效应模型计算合并HR。
主要发现
- BRAF V600E与总生存改善相关(HR=0.64;95%CI=0.45-0.92)。
- 无进展生存无统计学显著差异(HR=0.97;95%CI=0.7-1.36)。
- 亚组分析中BRAF V600E在儿童患者中显示改善生存的作用,但在成人中无预后价值。
临床怎么用
- BRAF突变可作为低级别胶质瘤的预后因素,但需结合年龄等因素综合评估。
局限性
- 需进一步研究纳入其他混杂因素以明确其预后价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Newly emerged molecular markers in gliomas provide prognostic values beyond the capabilities of histologic classification. BRAF mutation, especially BRAF V600E, is common in a subset of gliomas and may represent a potential prognostic marker. The aim of our study is to investigate the potential use of BRAF mutations on the prognosis of low-grade glioma patients. METHODS: Four electronic databases were searched for potential articles including PubMed, Web of Science, Embase, and Cochrane. Data of hazard ratio (HR) for overall survival and progression-free survival were directly obtained from original papers or indirectly estimated from the Kaplan-Meier curve. A random effect model weighted by inverse variance method was used to calculate the pooled HR. From 483 articles, we finally included 8 articles with 698 glioma patients for the final analysis. The overall estimates showed that BRAF V600E was associated with an improved overall survival in glioma patients (HR = 0.64; 95% confidence interval = 0.45-0.92). RESULTS: Results for progression-free survival, however, were not statistically significant (HR = 0.97; 95% confidence interval = 0.7-1.36). In subgroup analyses, BRAF V600E showed its effect in improving survival in pediatric patients but did not have prognostic value in adult. Our meta-analysis provides evidence that BRAF mutation has a favorable prognostic impact in low-grade gliomas, and its prognostic value might be dependent on patient age. CONCLUSIONS: This mutation can be used as a prognostic factor in low-grade glioma, but additional studies are required to clarify its prognostic value taking into account other confounding factors.
引用
- Kai Z, Dingyang L, Zhuanyi Y, et al. Prognostic Role of BRAF Mutation in Low-Grade Gliomas: Meta-analysis. World Neurosurg. 2020. PMID: 33316486. doi:10.1016/j.wneu.2020.12.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。